Physiomics reports fall in operating loss, rise in turnover

UK biology company Physiomics said operating loss dropped 6.3 per cent in the last half of 2012 as the group signed on new clients and progressed in research and development of products.

UK biology company Physiomics said operating loss dropped 6.3 per cent in the last half of 2012 as the group signed on new clients and progressed in research and development of products.

Operating loss came to £307,685, compared to £328,674 for the same period a year ago, as turnover increased 52.9% to £52,000.

Subscribe to MoneyWeek

Become a smarter, better informed investor with MoneyWeek.

The firm said it signed on a "top five" global pharmaceutical client during the period and was in discussions with others about licencing technology and entering into long-term contracts.

A £4.0m Standby Equity Distribution Agreement was signed with Yorkville, strengthening the position of the company for future growth and acquisition.

Advertisement - Article continues below

Physiomics advanced in developing two new technologies - DrugCARD database and Cardiac toxicity prediction service - which will be launched this year.

First stage of development of the group's Virtual Tumour Clinical, a computer model which analyses tumour cells, is underway as the company works closely with drug discovery and development groups.

"Significant progress has been made during the half year," the group said.

"The customer base has been increased, relationships with existing customers are progressing, new products are soon to come on line and the company's flagship Virtual Tumour Clinical project has begun in earnest, with large pharma already showing an interest in assisting its development.

"While progress on the sales front has been slower than the directors hoped, they believe that the company is establishing the level of credibility required to convert more prospects and is well positioned to deliver more stable sales in the near-term. Successful launch of Virtual Tumour Clinical has the potential to achieve a step-change in growth of revenues."

Shares rose 8.33% to 0.13 at 09:44 Thursday.

Advertisement - Article continues below


Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020
Share tips

Class acts going cheap: buy into Europe’s best bargains

Value investing appears to be making a comeback, while shares on this side of the Atlantic are more appealing on metrics such as price/earnings ratios…
16 Jan 2020

Most Popular


What does the coronavirus crisis mean for UK house prices?

With the whole country in lockdown, the UK property market is closed for business. John Stepek looks at what that means for UK house prices, housebuil…
27 Mar 2020

Coronavirus: what it means for your mortgage or your rent

Ruth Jackson-Kirby looks at all the key questions for owners, renters and landlords affected by the coronavirus crisis.
29 Mar 2020
Small business

Furlough: what does it mean and how does it affect me?

Many companies have “furloughed” employees after they have shut down because of the coronavirus. But what does furlough mean and how does the scheme w…
30 Mar 2020

Buy stocks for the long term, but buy very carefully

After the wild ride of the last couple of weeks, equities are no longer expensive. But if you do decide to buy, be very, very careful indeed, says Mer…
30 Mar 2020